Bank of America Securities analyst Tim Anderson reiterated a Hold rating on Pfizer today and set a price target of $28.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson’s rating is based on a combination of factors that reflect both the current performance and future outlook of Pfizer. The company’s recent financial results showed strong revenue and earnings per share, largely driven by its COVID-19 related products. However, despite these positive results, Pfizer maintained its revenue guidance for 2025, indicating potential uncertainties in the latter half of the year, particularly concerning COVID-19 revenues.
Additionally, while Pfizer’s valuation metrics such as its price-to-earnings ratio and dividend yield appear attractive, there are concerns about the long-term growth prospects of its major franchises due to upcoming patent expirations and increased competition. These factors contribute to a cautious outlook, leading to a Hold rating as the stock’s potential upside is balanced by these risks.
In another report released today, Citi also maintained a Hold rating on the stock with a $26.00 price target.